Interleukin 22R, Recombinant, Human (IL-22R, CRF2-9, IL-TIF R1, IL-10 Related T Cell-derived Inducib

IL-22 receptor, also known as IL-22Ralpha1 and CRF2-9, is an approximately 65 kD transmembrane glycoprotein in the type II cytokine receptor family (CRF). IL-22R contains a 211 aa extracellular domain (ECD) with two fibronectin type III repeats, and a 323 aa cytoplasmic domain. IL-22R associates with either IL-10Rbeta or IL-20Rbeta to form receptor complexes with distinct ligand selectivities. IL-10Rbeta is a shared subunit of the IL-10, -22, -26, -28, and -29 receptors, while IL-20Rbeta is a shared subunit of the IL-19, -20, -22R and -24 receptors. 1 IL-22R/IL-10 Rbeta is an IL-22 responsive receptor 2, 3 , and IL-22R/IL-20Rbeta is an IL-20 or IL-24 responsive receptor. 4, 5 IL-22R contains cytoplasmic motifs for interactions with signal transduction molecules, but formation of ternary complexes with IL-10Rbeta or IL-20Rbeta and the respective ligands is required for signal transduction. 2, 6 IL-22BP functions as a competitive antagonist by binding IL-22 and preventing its association with IL-22R. 7, 9 Even though it is a receptor for interleukins, IL-22R is not expressed on hematopoietic cells. 6, 10, 11 Instead, IL-22R expression is restricted to epithelial and stromal cells. 6, 10-13 IL-22R signaling promotes innate immune responses and wound healing at sites of infection and inflammation. This includes upregulation of antimicrobial, acute phase, proinflammatory, and extracellular matrix proteins as well as proteases. 3, 11, 13, 14 IL-22R signaling also promotes downregulation of proteins involved in keratinocyte differentiation. 3, 14 Within the ECD, human IL-22R shares 78%, 76%, and 83% aa sequence identity with mouse, rat, and canine IL-22R, respectively. It shares 22%-25% aa sequence identity with the ECDs of other class II receptors IL-10R, IL-20R, and IL-28R. Source: Recombinant protein corresponding to Pro18-Thr228 with a C-Terminal 6-His-Tag from human IL-22R, expressed in NS0 cells (NP_067081). SDS-PAGE: 34-38kD under reducing conditions, Activity: Measured by its ability to inhibit rhIL-22-induced IL-10 secretion by COLO 205 human colorectal adenocarcinoma cells. The ED50 for this effect is typically 1-4ug/ml in the presence of 1ng/mL of rhIL-22. Storage and Stability: Lyophilized powder may be stored at -20°C. Stable for 6 months after receipt at -20°C. Reconstitute with sterile PBS. Aliquot to avoid repeated freezing and thawing. Store at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.